Royce & Associates LP Has $7.67 Million Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Royce & Associates LP raised its holdings in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 10.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 986,073 shares of the medical instruments supplier's stock after buying an additional 96,138 shares during the quarter. Royce & Associates LP owned 2.43% of AngioDynamics worth $7,672,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Millennium Management LLC grew its stake in shares of AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier's stock worth $10,850,000 after acquiring an additional 529,861 shares during the last quarter. Western Standard LLC grew its position in AngioDynamics by 878.5% in the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier's stock worth $3,072,000 after purchasing an additional 469,906 shares during the last quarter. First Eagle Investment Management LLC bought a new position in shares of AngioDynamics during the 2nd quarter worth about $1,321,000. Systematic Financial Management LP raised its position in shares of AngioDynamics by 8.4% during the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock valued at $12,763,000 after buying an additional 162,972 shares during the last quarter. Finally, Kennedy Capital Management LLC lifted its stake in shares of AngioDynamics by 425.0% in the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier's stock valued at $1,117,000 after buying an additional 154,002 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Stock Performance

Shares of ANGO stock traded up $0.07 during trading hours on Monday, hitting $6.88. The company had a trading volume of 335,283 shares, compared to its average volume of 527,943. The firm has a market capitalization of $279.53 million, a price-to-earnings ratio of -1.10 and a beta of 0.67. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25. The firm's fifty day moving average is $7.00 and its 200 day moving average is $6.77.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to analysts' expectations of $67.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business's revenue was down 14.2% on a year-over-year basis. During the same period last year, the business earned ($0.12) earnings per share. On average, sell-side analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Ratings Changes

ANGO has been the subject of several recent research reports. Canaccord Genuity Group cut their price target on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a report on Friday, October 4th. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Friday, October 4th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the stock in a transaction dated Monday, October 7th. The stock was bought at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the purchase, the chief executive officer now owns 681,582 shares in the company, valued at $4,109,939.46. This represents a 3.02 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders bought 22,568 shares of company stock valued at $135,847. Corporate insiders own 5.40% of the company's stock.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.